TAT-11: Investigating the potential of 212Pb-rituximab as an Alpha-radioimmunotherapy for the Treatment of Non-Hodgkin's Lymphoma

Ottawa, ON, Canada (UroToday.com) The efficacy of Pb212-rituximab was tested in vitro against EL4-hCD20-Luc cells and shown to be effective relative to cold antibody or Pb212 with an irrelevant antibody. Dosing studies in mice showed 370 kBq to be safe( 740 kBq was unsafe, and 555 kBq caused some pain).

In vivo mice were injected with EL4-hCD20-Luc cells and then injected with 277.5 kBq of Pb212rituximabb after an interval of either 11, 20, or 30 days. Median overall survival was much better in the 11-day p.i. Group—105 days compared with 64 days for the most positive control sample.

The Renaissance of Radio Pharmaceuticals – A Commercial Perspective

Kathryn Hayashi, President and CEO, TRIUMF Innovations Dr. Mike Abrams, Biopharmaceutical Consultant

Other Radionuclides

Presented by: Stephanie Durand-Panateix, PhD, University of Limoges, Limoges, France

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada